One Penn Plaza
Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD, and in combination with anti-VEGF therapy in wet AMD patients.
128 articles with Ophthotech
Ophthotech Transitions to a Gene Therapy Focused Company Developing Treatments for Orphan Inherited Retinal Diseases and Changes Name to IVERIC bio
Ophthotech Corporation announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases (IRDs) with unmet medical needs, the Company is changing its name to IVERIC bio, Inc.
Ophthotech Corporation announced financial and operating results for the fourth quarter and full year ended December 31, 2018 and provided a business update.
Ophthotech Corporation to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, February 26, 2019
Ophthotech Corporation announced that it will report its fourth quarter and full year 2018 financial and operating results on Tuesday, February 26, 2019.
Ophthotech Announces the Addition of Ophthalmic Industry Leader, Calvin (Cal) W. Roberts, M.D., to Its Board of Directors
Dr. Roberts is Senior Vice President and Chief Medical Officer, Eye Care at Bausch Health Companies and Clinical Professor of Ophthalmology at Weill Medical College of Cornell University
Ophthotech Announces Results from Phase 2a Safety Trial of Zimura® in Combination with Lucentis® in Wet Age-Related Macular Degeneration
Trial was designed to evaluate the safety of different dosage regimens of Zimura combination therapy in wet AMD
Conference Call and Webcast to Discuss Q3 2018 Results and Two Pipeline Deals Announced Today
Ophthotech Expands Innovative Retinal Disease Pipeline with Acquisition of Versant Ventures’ Inception 4
- Ophthotech Gains HtrA1 Inhibitors to Treat Age-related Retinal Diseases -
Ophthotech Expands Gene Therapy Pipeline in Orphan Retinal Diseases with Exclusive Option for Novel Product Candidates to Treat Best Vitelliform Macular Dystrophy (Best Disease)
Ophthotech Enters into Second Series of Gene Therapy Agreements with the University of Pennsylvania and the University of Florida for Exclusive Option for Novel Product Candidates to Treat Best Disease
Ophthotech Corporation to Report Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, October 31, 2018
Conference call Wednesday, October 31, 2018 to discuss the Company’s financial results and provide a general business update.
Ophthotech Completes Patient Recruitment As Planned for its Phase 2b Clinical Trial of Zimura® Monotherapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Initial Top-line Zimura Geographic Atrophy Data Expected in the Fourth Quarter of 2019
Conference on Tuesday, October 9, 2018 at 8:30 a.m.
Scientific Data for Novel Adeno-Associated Virus Gene Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa Published in Proceedings of the National Academy of Sciences
Preclinical Proof-of-Concept Results in a Large Animal Model Published Online Ahead of Print in PNAS
(Conference Call and Webcast Today, August 1, 2018, at 8:00 a.m. ET)
Ophthotech Corporation to Report Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 1, 2018
Ophthotech Corporation announced that it will report its second quarter 2018 financial and operating results on Wednesday, August 1, 2018.
Ophthotech Enters into Gene Therapy Agreements with the University of Florida and the University of Pennsylvania
Expands Gene Therapy Portfolio with a Novel Mutation Independent Product Candidate for Autosomal Dominant Retinitis Pigmentosa
Ophthotech is a science-driven biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases
Ophthotech Corporation to Report First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018
Ophthotech Corporation announced that it will report its first quarter 2018 financial and operating results on Wednesday, May 9, 2018.
Ophthotech Completes Patient Recruitment in the Phase 2a Clinical Trial of Zimura® in Combination with Anti-VEGF Therapy in Wet Age-Related Macular Degeneration
Initial Top-line Data Expected by the End of 2018
phthotech collaborates with University of Massachusetts Medical School on novel technology for next-generation gene delivery technology and novel gene therapies for ophthalmic diseases
The Company also announced today that it has initiated an innovative gene therapy program focused on applying novel gene therapy technology to discover and develop new therapies for ocular diseases